Welcome to our dedicated page for Sera Prognostics news (Ticker: SERA), a resource for investors and traders seeking the latest updates and insights on Sera Prognostics stock.
Sera Prognostics, Inc. reports developments in women's health diagnostics, with news centered on its PreTRM® Test for spontaneous preterm birth risk prediction in asymptomatic singleton pregnancies. The company uses proteomics, bioinformatics and pregnancy biomarker information to support maternal and neonatal health.
Recurring updates include financial results, commercial adoption and payer engagement for PreTRM, clinical evidence from the PRIME study and related publications, investor presentations, healthcare conference activity, capital allocation and financing actions supporting commercialization.
Sera Prognostics (Nasdaq:SERA) appointed Mark Capone to its Board of Directors, effective July 1, 2026. Capone brings over 40 years of leadership in diagnostics and life sciences, including roles as CEO, President and COO at Myriad Genetics and earlier leadership at Eli Lilly.
According to Sera Prognostics, his experience commercializing complex diagnostics, navigating reimbursement and payer environments, and scaling commercial organizations is expected to support expansion of the company’s proteomics-based PreTRM test and its long-term growth strategy in maternal and neonatal health.
Sera Prognostics (Nasdaq:SERA) joined a multi-institutional program awarded up to $10.4 million by ARPA-H’s Making Obstetrics Care Smart (MOCS) initiative. The collaboration with UC San Diego and Allegro MicroSystems aims to develop a rapid point-of-care blood test to assess fetal hypoxia risk during labor.
Sera will apply its protein biomarker discovery and validation expertise to identify signatures of placental dysfunction, fetal stress, or hypoxia risk, supporting more precise, data-driven intervention decisions in childbirth.
Sera Prognostics (Nasdaq:SERA) highlighted new Illinois legislation requiring Medicaid to cover prescribed proteomic blood tests that assess spontaneous preterm birth risk, plus related care management services and interventions. Sera’s PreTRM Test is described as the only broadly validated, commercially available blood-based test of its kind.
Illinois records about 13,042 preterm births annually and approximately 50,000 Medicaid births, where expanded access to early risk assessment tools may support better maternal and neonatal outcomes and help manage financial burdens on Medicaid programs.
Sera Prognostics (Nasdaq: SERA) announced that board member Jeff Elliott will step down from its Board of Directors effective June 4, 2026, and will not stand for re-election at the upcoming Annual Meeting.
Elliott, who joined in March 2025, cited increasing demands on his time. Sera is in advanced discussions with highly qualified candidates to join the board and expects to announce a new appointment soon as part of its focus on strong corporate governance and leadership continuity.
Sera Prognostics (Nasdaq: SERA) reported first quarter 2026 results and key commercial and clinical milestones on May 6, 2026. Highlights include publication of the randomized PRIME trial showing reduced early preterm births (−56% <32 weeks; −32% <35 weeks), NICU admissions (−20%), and neonatal morbidity (−20%). The company launched a third partnership to reach >350 providers, is in active talks with 13 payers across 15 states, and is preparing a CE marking dossier for mid‑year submission. Q1 revenue was $14,000, net loss was $8.4 million, and cash and securities totaled $86.8 million, with a cash runway extended through 2029.
Sera Prognostics (Nasdaq: SERA) will report first quarter fiscal 2026 results on Wednesday, May 6, 2026, after market close and will host a conference call and live webcast at 5:00 p.m. ET. A press release with results and highlights will be distributed before the call.
Live audio and archived replay will be available on the company's Investors page at www.sera.com and the webcast will be archived for one year.
Sera Prognostics (Nasdaq: SERA) reported fourth-quarter and full-year 2025 results and operational progress on March 18, 2026. Key points: landmark PRIME randomized trial showed large reductions in earliest preterm births and neonatal complications, Sera completed a $57.5M follow-on financing in Feb 2025, and year-end cash totaled ~$95.8M, which the company expects to fund operations into 2028.
Full-year revenue was $81,000; 2025 R&D expense declined to $13.2M as the company shifts from pivotal studies toward commercialization.
Sera Prognostics (Nasdaq: SERA) will report fourth quarter and fiscal year 2025 financial results on Wednesday, March 18, 2026, after market close.
The company will host a conference call and live webcast at 5:00 p.m. ET to discuss operational highlights, financial results and key topics. A press release with results will be distributed before the call. Live audio and an archived webcast will be available on the Investors page at www.sera.com for one year.
Sera Prognostics (Nasdaq: SERA) will present at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026 at 1:10 p.m. ET. Management will host a fireside chat and hold one-on-one investor meetings during the March 2-4, 2026 conference in Boston.
A live webcast and replay will be available via the company’s Investors page at www.sera.com.
Sera Prognostics (NASDAQ: SERA) reported PRIME, a randomized trial of 5,018 women published Jan 7, 2026 in PREGNANCY, showing the PreTRM blood test plus targeted interventions reduced earliest preterm births and newborn complications.
Key results: 56% fewer births before 32 weeks, 32% fewer before 35 weeks, 20% fewer NICU admissions, and a 20% reduction in odds of neonatal morbidity. The study found one NICU day saved per 4.2 patients screened and a number-needed-to-screen of 39 to prevent one NICU admission.